BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma-Lauer Y, Zheng Y, Malešević M, von Brunn B, Fischer G, von Brunn A. Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. Antiviral Res 2020;173:104620. [PMID: 31634494 DOI: 10.1016/j.antiviral.2019.104620] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Rodriguez-peralvarez M, Salcedo M, Colmenero J, Pons JA. Modulating immunosuppression in liver transplant patients with COVID-19. Gut 2021;70:1412-4. [DOI: 10.1136/gutjnl-2020-322620] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
2 Liang W, Zhang Y, Li M, Al-Shaebi F, Li J, Zhang J, Wei L. Cyclophilin A Inhibits Human Respiratory Syncytial Virus (RSV) Replication by Binding to RSV-N through Its PPIase Activity. J Virol 2021;95:e0056321. [PMID: 34011546 DOI: 10.1128/JVI.00563-21] [Reference Citation Analysis]
3 Khan S, Siddique R, Shereen MA, Ali A, Liu J, Bai Q, Bashir N, Xue M. Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options. J Clin Microbiol. 2020;58. [PMID: 32161092 DOI: 10.1128/jcm.00187-20] [Cited by in Crossref: 92] [Cited by in F6Publishing: 80] [Article Influence: 46.0] [Reference Citation Analysis]
4 Parente A, Manzia TM, Angelico R, Tirotta F, Muiesan P, Tisone G, Framarino Dei Malatesta M. COVID-19, liver transplant, and immunosuppression: Allies or foes? Transpl Infect Dis 2021;23:e13417. [PMID: 32666588 DOI: 10.1111/tid.13417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Emadi SN, Hamzelou S, Saffarian Z, Shakoei S. Challenges in the treatment of a patient with toxic epidermal necrolysis associated with COVID-19: A case report. Dermatol Ther 2021;34:e14656. [PMID: 33301196 DOI: 10.1111/dth.14656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liao Y, Luo D, Peng K, Zeng Y. Cyclophilin A: a key player for etiological agent infection. Appl Microbiol Biotechnol 2021;105:1365-77. [PMID: 33492451 DOI: 10.1007/s00253-021-11115-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Tripathi D, Sodani M, Gupta PK, Kulkarni S. Host directed therapies: COVID-19 and beyond. Curr Res Pharmacol Drug Discov 2021;2:100058. [PMID: 34870156 DOI: 10.1016/j.crphar.2021.100058] [Reference Citation Analysis]
8 Prasad K, Ahamad S, Kanipakam H, Gupta D, Kumar V. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine. ACS Chem Neurosci 2021;12:930-44. [PMID: 33606519 DOI: 10.1021/acschemneuro.1c00019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 NasrAllah MM, Osman NA, Elalfy M, Malvezzi P, Rostaing L. Transplantation in the era of the Covid-19 pandemic: How should transplant patients and programs be handled? Rev Med Virol 2021;31:1-9. [PMID: 32954602 DOI: 10.1002/rmv.2149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 [DOI: 10.1101/2020.06.19.161042] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
11 Maggiore U, Abramowicz D, Crespo M, Mariat C, Mjoen G, Peruzzi L, Sever MS, Oniscu GC, Hilbrands L, Watschinger B. How should I manage immunosuppression in a kidney transplant patient with COVID-19? Nephrol Dial Transplant. 2020;35:899-904. [PMID: 32441741 DOI: 10.1093/ndt/gfaa130] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 22.5] [Reference Citation Analysis]
12 Gallardo-Flores CE, Colpitts CC. Cyclophilins and Their Roles in Hepatitis C Virus and Flavivirus Infections: Perspectives for Novel Antiviral Approaches. Pathogens 2021;10:902. [PMID: 34358052 DOI: 10.3390/pathogens10070902] [Reference Citation Analysis]
13 Softic L, Brillet R, Berry F, Ahnou N, Nevers Q, Morin-Dewaele M, Hamadat S, Bruscella P, Fourati S, Pawlotsky JM, Ahmed-Belkacem A. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). Antimicrob Agents Chemother 2020;64:e00876-20. [PMID: 32376613 DOI: 10.1128/AAC.00876-20] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
14 Latief M, Shafi O, Hassan Z, Farooq S, Abbas F. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in Kidney transplant patients: A case series and literature review. Med J Islam Repub Iran 2021;35:17. [PMID: 33996668 DOI: 10.47176/mjiri.35.17] [Reference Citation Analysis]
15 Glowacka P, Rudnicka L, Warszawik-Hendzel O, Sikora M, Goldust M, Gajda P, Stochmal A, Blicharz L, Rakowska A, Olszewska M. The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections. Biology (Basel) 2020;9:E192. [PMID: 32731331 DOI: 10.3390/biology9080192] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
16 Santos A, Sousa LL, Calça R, Lima A, Nascimento C, Jorge C, Adragão T, Bruges M, Peres S, Weigert A. SARS-CoV-2 infection in kidney transplant recipients: clinical impact and outcomes - a single center experience. J Bras Nefrol 2021:S0101-28002021005078301. [PMID: 34812470 DOI: 10.1590/2175-8239-JBN-2021-0164] [Reference Citation Analysis]
17 Angelico R, Blasi F, Manzia TM, Toti L, Tisone G, Cacciola R. The Management of Immunosuppression in Kidney Transplant Recipients with COVID-19 Disease: An Update and Systematic Review of the Literature. Medicina (Kaunas) 2021;57:435. [PMID: 33946462 DOI: 10.3390/medicina57050435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Dittmar M, Lee JS, Whig K, Segrist E, Li M, Kamalia B, Castellana L, Ayyanathan K, Cardenas-Diaz FL, Morrisey EE, Truitt R, Yang W, Jurado K, Samby K, Ramage H, Schultz DC, Cherry S. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Rep 2021;35:108959. [PMID: 33811811 DOI: 10.1016/j.celrep.2021.108959] [Cited by in Crossref: 27] [Cited by in F6Publishing: 38] [Article Influence: 27.0] [Reference Citation Analysis]
19 Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM, Roda-Santacruz A, González-Cortijo L, Sotres-Fernández G, Martí-Ballesteros EM, Luque-Pinilla JM, Almagro-Casado E, La Coma-Lanuza FJ, Barrena-Puertas R, Malo-Benages EJ, Monforte-Gómez MJ, Diez-Munar R, Merino-Lanza E, Comeche-Casanova L, Remirez-de-Esparza-Otero M, Correyero-Plaza M, Recio-Rodríguez M, Rodríguez-López M, Sánchez-Manzano MD, Andreu-Vázquez C, Thuissard-Vasallo IJ, María-Tomé JME, Carnevali-Ruiz D. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine 2020;28:100591. [PMID: 33078138 DOI: 10.1016/j.eclinm.2020.100591] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 16.0] [Reference Citation Analysis]
20 Wong NA, Saier MH Jr. The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis. Int J Mol Sci 2021;22:1308. [PMID: 33525632 DOI: 10.3390/ijms22031308] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
21 Liu C, von Brunn A, Zhu D. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19. Med Drug Discov 2020;7:100056. [PMID: 32835213 DOI: 10.1016/j.medidd.2020.100056] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
22 Cavagna L, Seminari E, Zanframundo G, Gregorini M, Di Matteo A, Rampino T, Montecucco C, Pelenghi S, Cattadori B, Pattonieri EF, Vitulo P, Bertani A, Sambataro G, Vancheri C, Biglia A, Bozzalla-Cassione E, Bonetto V, Monti MC, Ticozzelli E, Turco A, Oggionni T, Corsico A, Bertuccio F, Zuccaro V, Codullo V, Morosini M, Marena C, Gnecchi M, Pellegrini C, Meloni F. Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy. Microorganisms 2020;8:E977. [PMID: 32629788 DOI: 10.3390/microorganisms8070977] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
23 Poulsen NN, von Brunn A, Hornum M, Blomberg Jensen M. Cyclosporine and COVID-19: Risk or favorable? Am J Transplant 2020;20:2975-82. [PMID: 32777170 DOI: 10.1111/ajt.16250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
24 Rossi G, Galosi L, Gavazza A, Cerquetella M, Mangiaterra S. Therapeutic approaches to coronavirus infection according to "One Health" concept. Res Vet Sci 2021;136:81-8. [PMID: 33588098 DOI: 10.1016/j.rvsc.2021.02.009] [Reference Citation Analysis]
25 Batalha PN, Forezi LSM, Lima CGS, Pauli FP, Boechat FCS, de Souza MCBV, Cunha AC, Ferreira VF, da Silva FC. Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches. Bioorg Chem 2021;106:104488. [PMID: 33261844 DOI: 10.1016/j.bioorg.2020.104488] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
26 Crespo M, Pérez-Sáez MJ, Redondo-Pachón D, Llinàs-Mallol L, Montero MM, Villar-García J, Arias-Cabrales C, Buxeda A, Burballa C, Vázquez S, López T, Moreno F, Mir M, Outón S, Sierra A, Collado S, Barrios C, Rodríguez E, Sans L, Barbosa F, Cao H, Arenas MD, Güerri-Fernández R, Horcajada JP, Pascual J. COVID-19 in elderly kidney transplant recipients. Am J Transplant 2020;20:2883-9. [PMID: 32471001 DOI: 10.1111/ajt.16096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
27 Kant S, Menez SP, Hanouneh M, Fine DM, Crews DC, Brennan DC, Sperati CJ, Jaar BG. The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation. BMC Nephrol 2020;21:449. [PMID: 33109103 DOI: 10.1186/s12882-020-02112-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
28 Gálvez-Romero JL, Deveaux-Homs J, Real-Ramírez FA, Palmeros-Rojas O, Pedraza-Sánchez S. Reply letter to: Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: Are concentrations required clinically achievable? J Intern Med 2021;289:928-9. [PMID: 33822418 DOI: 10.1111/joim.13278] [Reference Citation Analysis]
29 Becchetti C, Gschwend SG, Dufour JF, Banz V. COVID-19 in Liver Transplant Recipients: A Systematic Review. J Clin Med 2021;10:4015. [PMID: 34501463 DOI: 10.3390/jcm10174015] [Reference Citation Analysis]
30 Schoot TS, Kerckhoffs APM, Hilbrands LB, van Marum RJ. Immunosuppressive Drugs and COVID-19: A Review. Front Pharmacol 2020;11:1333. [PMID: 32982743 DOI: 10.3389/fphar.2020.01333] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 14.0] [Reference Citation Analysis]
31 . Pharmacological activation of STING blocks SARS-CoV-2 infection. Sci Immunol 2021;6:eabi9007. [PMID: 34010142 DOI: 10.1126/sciimmunol.abi9007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
32 Wang M, Hu C, Zhao Q, Feng R, Wang Q, Cai H, Guo Z, Xu K, Luo W, Guo C, Zhang S, Chen C, Zhu C, Wang H, Chen Y, Ma L, Zhan P, Cao J, Huang S, Yang MJ, Fang Y, Zhu S, Yang Y. Acute psychological impact on COVID-19 patients in Hubei: a multicenter observational study. Transl Psychiatry 2021;11:133. [PMID: 33602920 DOI: 10.1038/s41398-021-01259-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
33 Wang B, Huang J, Hsin M, Chen J, Lin H. First lung transplant in Wuhan for a critical and elderly COVID-19 patient. Immun Inflamm Dis 2021;9:1500-7. [PMID: 34469048 DOI: 10.1002/iid3.501] [Reference Citation Analysis]
34 Nickerson AM, Sobotka LA, Kelly SG. PRO: Liver Transplantation in the Times of COVID-19: "To Transplant or Not to Transplant". Clin Liver Dis (Hoboken) 2021. [PMID: 34518778 DOI: 10.1002/cld.1131] [Reference Citation Analysis]
35 Devresse A, De Greef J, Yombi JC, Belkhir L, Goffin E, Kanaan N. Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients. Transplantation Direct 2022;8:e1292. [DOI: 10.1097/txd.0000000000001292] [Reference Citation Analysis]
36 Saxena A. Drug targets for COVID-19 therapeutics: Ongoing global efforts. J Biosci 2020;45:87. [PMID: 32661214 [PMID: 32661214 DOI: 10.1007/s12038-020-00067-w] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 17.5] [Reference Citation Analysis]
37 Sebastian S, Gonzalez HA, Peyrin-Biroulet L. Safety of Drugs During Previous and Current Coronavirus Pandemics: Lessons for Inflammatory Bowel Disease. J Crohns Colitis. 2020;14:1632-1643. [PMID: 32520312 DOI: 10.1093/ecco-jcc/jjaa120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
38 Laurie K, Holcomb D, Kames J, Komar AA, DiCuccio M, Ibla JC, Kimchi-Sarfaty C. In Silico Evaluation of Cyclophilin Inhibitors as Potential Treatment for SARS-CoV-2. Open Forum Infect Dis 2021;8:ofab189. [PMID: 34109257 DOI: 10.1093/ofid/ofab189] [Reference Citation Analysis]
39 Pawlotsky JM. COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir. Clin Infect Dis 2020;71:2191-4. [PMID: 32409832 DOI: 10.1093/cid/ciaa587] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
40 Aghamirza Moghim Aliabadi H, Eivazzadeh‐keihan R, Beig Parikhani A, Fattahi Mehraban S, Maleki A, Fereshteh S, Bazaz M, Zolriasatein A, Bozorgnia B, Rahmati S, Saberi F, Yousefi Najafabadi Z, Damough S, Mohseni S, Salehzadeh H, Khakyzadeh V, Madanchi H, Kardar GA, Zarrintaj P, Saeb MR, Mozafari M. COVID‐19: A systematic review and update on prevention, diagnosis, and treatment. MedComm 2022;3. [DOI: 10.1002/mco2.115] [Reference Citation Analysis]